Clinical studyApplication of ambulatory blood pressure monitoring in differentiating between antihypertensive agents☆
References (28)
- et al.
Ambulatory blood pressure monitoring in the evaluation of drug efficacy
Am Heart J
(1991) Clinical differences between beta-adrenergic blocking agents: implications for therapeutic substitutions
Am Heart J
(1987)- et al.
Validation of portable noninvasive blood pressure monitoring devices: comparisons with intra-arterial and sphygmomanometer measurements
Am Heart J
(1988) - et al.
The circadian blood pressure pattern in ambulatory normal subjects
Am J Cardiol
(1984) - et al.
Blood pressure, stroke, and coronary heart disease: part I, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias
Lancet
(1990) - et al.
Blood pressure, stroke and coronary heart disease: part 2, short-term reductions in blood pressure: overview of randomized drug trials in their epidemiological context
Lancet
(1990) - et al.
Circadian variation of blood pressure
Lancet
(1978) Antihypertensive treatment, myocardial infarction, and nocturnal myocardial ischemia
Lancet
(1988)- et al.
Blood pressure load—a better determinant of hypertension
- et al.
Assessment of the daily blood pressure load as a determinant of cardiac function in patients with mild-to-moderate hypertension
Am Heart J
(1989)
Characterization of antihypertensive therapy by whole-day blood pressure monitoring
JAMA
Assessing duration of antihypertensive effects with whole-day blood pressure monitoring
Arch Intern Med
Morning increase in onset of ischemic stroke
Stroke
Circadian variation in the frequency of onset of acute myocardial infarction
N Engl J Med
Cited by (95)
Ambulatory Blood Pressure Monitoring in Clinical Hypertension Management
2023, Hypertension: A Companion to Braunwald's Heart DiseaseAmbulatory Blood Pressure Monitoring in Clinical Hypertension Management
2018, Hypertension: A Companion to Braunwald's Heart DiseaseKidney function and population-based outcomes of initiating oral atenolol versus metoprolol tartrate in older adults
2014, American Journal of Kidney DiseasesCitation Excerpt :Comparing once-daily atenolol to an extended-release preparation of once-daily metoprolol (eg, metoprolol succinate) may have given a different result, but could not be studied in our region because metoprolol succinate is not an approved drug on our provincial formulary. Dosing atenolol twice daily also is possible, which may improve blood pressure control compared to once-daily dosing provided there is good adherence.42 Third, metoprolol tartrate shows higher first-pass metabolism effects than atenolol, which could result in less of the drug reaching the systemic circulation.
Contemporary use of β-blockers: Clinical relevance of subclassification
2014, Canadian Journal of CardiologyCitation Excerpt :In fact, nonselective agents, by their blocking effect on β-2 vasodilatory receptors, might be less effective than cardioselective agents, those agents demonstrating less systolic BP variability compared with nonselective agents.14 Bisoprolol 10 to 20 mg once daily has indeed been shown to lower BP more effectively than atenolol 50 to 100 mg once daily, a moderately cardioselective β-blocker.43 The Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)44 examined 19,257 hypertensive patients with at least 3 other risk factors and treated with either an amlodipine-based treatment or an atenolol-based treatment.
Biowaiver monograph for immediate-release solid oral dosage forms: Bisoprolol fumarate
2014, Journal of Pharmaceutical SciencesCitation Excerpt :Bisopolol is indicated in the treatment of stable chronic heart failure with reduced systolic ventricular function in addition to angiotensin converting enzyme inhibitors, diuretics and optionally, cardiac glycosides.5,6 It is also indicated in the suppression of atrial fibrillation5,7,8 and has antihypertensive efficacy.9-12 Preclinical studies including conventional safety pharmacology, repeated dose toxicity, genotoxicity, or carcinogenicity have not revealed any special hazard to humans.
Differences in mean and variability of heart rate and ambulatory rate-pressure product when valsartan or carvedilol is added to lisinopril
2012, Journal of the American Society of HypertensionCitation Excerpt :However, the interpretation that increased blood pressure variability with atenolol accounts for inferior CVD outcomes hinges on a major flaw in the study design and in routine clinical practice: that atenolol can be reliably administered once daily. This assertion is clearly not true because atenolol has an effective pharmacodynamic half-life that is substantially less than 24 hours.29 Thus, if dosed in the morning, atenolol cannot be optimally effective at reducing the surge in BP and the accompanying increases in event rates for stroke30 and CVD31 that occur the next day in the early morning hours.
- ☆
This work was supported by a grant from Lederle Laboratories, Pearl River, New York. Presented in part at the 93rd Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics, Orlando, Florida, March 18, 1992.